this beneficial effect of dermatan sulfate appears to be unrelated to anti-factor xa activity either endogenous to dermatan sulfate itself ( which is unlikely since it does not catalyze factor xa inhibition ) or to anti-factor xa activity associated with other glycosaminoglycans released into the circulation following dermatan sulfate administration since this activity is less than that associated with heparin treatment .
C0017973
glycosaminoglycans
C0019134
heparin